Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient

Study Identifier:
CCD-01535AC1-02
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
EU CT ID:
N/A
Study Contact Information:
N/A
Study Complete

Trial Documents

Clinical Study Report
Available Languages: English
Plain Language Summary
Available Languages: Chinese (China), English

Study Details

Medical Condition
  • Chronic Obstructive Pulmonary Disease
Study Drug
  • Drug: CHF 1535 100/6 µg pMDI plus Symbicort® Turbohaler® Placebo
  • Drug: Symbicort® Turbohaler® plus CHF 1535 pMDI Placebo
Date
Jul 2018 - May 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 40+ years
Requirements Information
Healthy Volunteers
No

Protocol Summary

The purpose of the study is to demonstrate the non-inferiority of CHF1535 pMDI versus Symbicort® Turbohaler® in terms of lung function parameters and patients reported outcomes and to assess its safety and tolerability.

Study Locations

Location
Status
Location
Site 15604 - Anhui Provincial Hospital
Hefei, Anhui, China, 230001
Status
N/A
Location
Site 15635 - The Second Hospital of Anhui Medical Hospital
Hefei, Anhui, China, 231200
Status
N/A
Location
Site 15613 - Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100050
Status
N/A
Location
Site 15611 - Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China, 100053
Status
N/A
Location
Site 15640 - Peking University Shougang Hospital
Beijing, Beijing Municipality, China, 100144
Status
N/A
Location
Site 15626 - Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191
Status
N/A
Go to page